Form 4: Precigen CLO Donald Lehr Reports RSU Vesting

Chief Legal Officer Donald P. Lehr acquired 62,500 shares of Precigen common stock through the vesting of restricted stock units.

Summary

• Donald P. Lehr, Chief Legal Officer of Precigen, Inc., acquired 62,500 shares of common stock on May 23, 2026.
• The acquisition resulted from the vesting of restricted stock units (RSUs) granted on June 26, 2025.
• Following this transaction, the reporting person holds a total of 784,592 shares of Precigen common stock.
• The remaining RSUs from the original grant are scheduled to vest in equal quarterly installments over the next three years.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard administrative update regarding executive equity compensation rather than a change in company strategy or financial outlook.

Positives

• The transaction reflects the fulfillment of equity-based compensation, aligning the interests of the Chief Legal Officer with shareholders.

Negatives

• None identified; this is a routine disclosure of equity compensation vesting.

Risks

• The value of the acquired shares is subject to market volatility inherent in the biotechnology sector.

Future Outlook

The remaining RSUs from the June 2025 grant will continue to vest in equal quarterly installments over the next three years.

Industry Context

StockSavvy.ai notes that routine equity vesting for executive officers is standard practice in the biotechnology industry to ensure long-term retention and alignment with corporate performance goals.

Comparison to Industry Standards

• The vesting schedule and equity compensation structure are consistent with standard executive compensation packages for mid-cap biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders as this is a pre-planned equity compensation event.

Next Steps

• Quarterly vesting of remaining restricted stock units over the next three years.

Key Dates

Keywords

Precigen, PGEN, Form 4, Insider Trading, Equity Compensation, Biotechnology